Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Susoctocog alfa - Takeda

Next Previous
X
Search
Drug Profile

Susoctocog alfa - Takeda

Alternative Names: B-Domain deleted recombinant porcine factor VIII (OBI-1); BAX 802; BAX801; Factor VIII - Ipsen; FVIII - Ipsen; OBI-1; Obizur; PFVIII; Porcine FVIII; Recombinant porcine factor VIII - Inspiration/Ipsen; RpfVIII; SHP672; TAK 672

Latest Information Update: 03 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emory University
  • Developer Baxter International; Takeda
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor VII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 26 Mar 2024 Registered for Haemophilia A in Japan (IV)
  • 29 Feb 2024 Registered for Haemophilia A in China (IV), before February 2024 (Takeda pipeline, May 2024)
  • 30 Jun 2023 Preregistration for Haemophilia A in Japan (IV) (Takeda pipeline; July 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top